Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mendelics | RCV000986740 | SCV001135845 | likely pathogenic | Lynch syndrome 5 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002346194 | SCV002619358 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-23 | criteria provided, single submitter | clinical testing | The p.G1216R variant (also known as c.3646G>C), located in coding exon 7 of the MSH6 gene, results from a G to C substitution at nucleotide position 3646. The glycine at codon 1216 is replaced by arginine, an amino acid with dissimilar properties. However, this change occurs in the last base pair of coding exon 7, which makes it likely to have some effect on normal mRNA splicing. This nucleotide position is highly conserved in available vertebrate species. This amino acid position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. In addition, as a missense substitution, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Baylor Genetics | RCV003467542 | SCV004195792 | uncertain significance | Endometrial carcinoma | 2023-05-11 | criteria provided, single submitter | clinical testing |